Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $242.00 price target on Biogen (NASDAQ: BIIB).The analyst commented, "We hosted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
